---
title: "Melissa officinalis (Lemon Balm) - Complete Evidence-Based Clinical Monograph"
category: "Herbal Medicine Monograph"
tags: ["lemon balm", "Melissa officinalis", "herbal medicine", "clinical evidence", "pharmacology", "phytotherapy", "evidence-based medicine", "anxiety", "sleep", "herpes", "GABA", "AChE inhibition"]
botanical_name: "Melissa officinalis"
common_names: ["lemon balm", "balm mint", "bee balm", "sweet balm"]
plant_family: "Lamiaceae"
date: "2025-11-11"
source: "Clinical Research Compilation - PubMed Verified"
document_type: "Complete Clinical Monograph"
target_audience: "Healthcare Practitioners, Clinical Researchers"
version: "1.0"
quality_status: "PubMed Citations Verified - Full Evidence Analysis"
evidence_grading: "Strong, Moderate, Conflicting evidence with statistical analysis"
development_status: "Complete - Ready for Vector Store"
---

# *Melissa officinalis* L. (Lemon Balm): A Comprehensive Scientific Monograph on Phytochemistry, Mechanisms, and Clinical Evidence

**DOCUMENT CONTEXT:** This comprehensive clinical monograph provides healthcare professionals with evidence-based information on Lemon Balm (Melissa officinalis). All PubMed/PMC citations have been verified with DOI links to original research. Document optimized for vector store embedding with semantic structure and rich metadata.

**MEDICAL DISCLAIMER**: This monograph is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.

## [semantic_index] Semantic Index (Section Map)

- [overview] Document Overview and Purpose
- [executive_summary] Executive Summary
- [introduction] Introduction: A 2,000-Year Pharmacopoeia
- [phytochemistry] Phytochemical Profile: The Bioactive Arsenal
- [pharmacology] Pharmacology and Mechanisms of Action
- [clinical_evidence_cns] Clinical Evidence Review: CNS and Psychological Health
- [clinical_evidence_systemic] Clinical Evidence Review: Systemic and Topical Applications
- [pharmacokinetics] Pharmacokinetics, Formulation, and Bioavailability
- [safety] Safety, Contraindications, and Interactions
- [conclusions] Concluding Synthesis and Future Directives
- [references] Bibliography & References

## [executive_summary] Executive Summary

*Melissa officinalis* L. (lemon balm), a perennial herb with a 2,000-year history of use in traditional medicine 1, has emerged as a subject of intensive modern pharmacological and clinical investigation. This report synthesizes the current body of evidence from its foundational phytochemistry to its complex mechanisms of action and the results of systematic reviews and randomized controlled trials (RCTs).

The therapeutic potential of *M. officinalis* is derived from a complex phytochemical matrix, including phenolic acids (predominantly rosmarinic acid), volatile terpenoids (citral, citronellal), triterpenoids (ursolic and oleanolic acid), and flavonoids.3 These compounds exert multi-target effects, most notably through modulation of the GABAergic system (GABA-T inhibition and $GABA\_A$ receptor stimulation) to produce anxiolytic and sedative effects 6, and through inhibition of acetylcholinesterase (AChE) to support cognitive function.1

A critical analysis of the clinical evidence reveals distinct tiers of efficacy:

* **Strong Evidence:** The most robust and consistent evidence supports the **topical application of *M. officinalis* extract for *Herpes labialis* (cold sores)**. A systematic review of seven RCTs (n=1,250) confirmed that *M. officinalis* formulations consistently reduce pain, swelling, and lesion size, rivaling or exceeding placebo and, in some cases, acyclovir.10 This is underpinned by a unique mechanism of blocking viral attachment to host cells, which may prevent drug resistance.12  
* **Moderate Evidence (with Caveats):** Systematic reviews and meta-analyses (SRMAs) demonstrate **statistically significant benefits** for several conditions:  
  * **Anxiety and Depression:** MO significantly improves anxiety (SMD \-0.98) and depression (SMD \-0.47) versus placebo.14  
  * **Insomnia:** MO, particularly in high-bioavailability forms, significantly improves sleep quality, reduces insomnia scores (p=0.003), and objectively increases deep Slow Wave Sleep (SWS) duration.15  
  * Dyslipidemia: MO consumption significantly reduces total cholesterol (TC), triglycerides (TG), and LDL-cholesterol.16  
    This evidence is downgraded to "moderate" because the SRMA authors consistently warn of "high heterogeneity," "small number of studies," and "risk of bias" 14, warranting cautious interpretation.  
* **Conflicting Evidence:** The data for **cognitive decline** is in direct conflict. A 2003 RCT in patients with mild-to-moderate Alzheimer’s Disease (AD) found significant cognitive improvement.19 Conversely, a large, 2-year (2022) RCT in patients with Mild Cognitive Impairment (MCI) found no overall benefit.20 This discrepancy likely stems from a population-mechanism mismatch, as MO's AChE-inhibiting action is a relevant target for AD but not necessarily for MCI.

**Safety and Interactions:** *M. officinalis* is generally recognized as safe (GRAS) and well-tolerated in clinical trials, with no evidence of hepatotoxicity.21 However, several critical risks exist:

1. **Thyroid Contraindication:** *M. officinalis* is **strongly contraindicated in patients with thyroid disease, particularly hypothyroidism**. It can block TSH binding to its receptor and interfere with thyroid hormone replacement therapy.23  
2. **Sedative Interaction:** Its GABAergic mechanism **potentiates other CNS depressants**, including alcohol and benzodiazepines.26  
3. **Dependence Risk:** A case report of withdrawal symptoms (tremor, anxiety) upon cessation of long-term use suggests a potential for physical dependence, confirming its potent GABAergic activity.26

**Formulation and Future Directives:** The "poor bioavailability" and "fast metabolism" of key polyphenols like rosmarinic acid 27 are major hurdles. Next-generation Phytosome$^{\\texttrademark}$ formulations, which demonstrate over 4-fold greater *in vitro* potency 8, show promise in delivering more reliable clinical outcomes.15 Future research must prioritize resolving the cognitive conflict, confirming the therapeutic potential in hypertension, and addressing the high risk of product adulteration.30

## [introduction] Introduction: A 2,000-Year Pharmacopoeia

### **2.1. From Traditional Medicine to Modern Clinical Targets**

*Melissa officinalis* L., commonly known as lemon balm, is a perennial herb of the mint family (Lamiaceae).23 Its use in traditional and folk medicine is not recent; it boasts an extensive 2,000-year history of continuous documentation.1 Its medicinal properties were described in *Historica Plantarum* around 300 B.C. and in Dioscorides' foundational *De Materia Medica* (c. 50–80 B.C.).1

Traditionally, its applications have been broad. It was recorded as a "cardiac tonic" 16, a carminative to alleviate digestive issues 1, and a surgical dressing for wounds.32 However, its most enduring traditional reputation is as a calmative agent—used to promote relaxation and sleep 1, strengthen memory, and relieve stress-induced headaches.32

This extensive historical use has provided a roadmap for modern pharmacological inquiry. Contemporary clinical trials are now investigating these exact traditional indications using rigorous scientific methods. The traditional use as a "cardiac tonic" is being tested in RCTs for dyslipidemia 16 and hypertension.34 The traditional use for memory and mood is being directly tested in RCTs for anxiety 1, depression 35, and neurodegenerative conditions like Alzheimer's disease.19

### **2.2. Phytochemical Profile: The Bioactive Arsenal**

The wide-ranging pharmacological effects of *M. officinalis* are not attributed to a single molecule but to a complex and synergistic array of phytochemicals.1 The primary classes of bioactive compounds identified in the plant are:

* **Phenolic Acids:** This class is central to its activity. **Rosmarinic acid (RA)** is consistently identified as the "predominant active ingredient".4 Other notable phenolic acids include caffeic acid and chlorogenic acid.3  
* **Volatile Compounds (Essential Oils):** This class provides the plant's characteristic mild lemon aroma.23 The essential oil is rich in monoterpenes, primarily the isomers **geranial (citral a) and neral (citral b)**, as well as **citronellal** and geraniol.3  
* **Triterpenoids:** The triterpenes **ursolic acid and oleanolic acid** are consistently identified as key non-volatile components.1  
* **Flavonoids:** The plant also contains several antioxidant flavonoids, including quercetin, rhamnocitrin, and luteolin.3

### **2.3. The Standardization Imperative: Adulteration and Variability**

A critical issue that complicates both the commercial use and scientific study of *M. officinalis* is the profound variability and high risk of adulteration in raw materials and extracts.30

This variability begins with extraction. The resulting chemical profile is highly dependent on the solvent used. Research demonstrates that a 70% ethanol solution is the "best solvent for extracting biologically active compounds," yielding significantly higher concentrations than a 40% ethanol solution.4 Aqueous (water) extracts, while high in water-soluble rosmarinic acid, may be deficient in other important lipophilic compounds.4

This inherent variability is exploited in the marketplace. *Melissa officinalis* has been identified as a nutraceutical at "high risk of adulteration and contamination".30 Adulteration methods include dilution with cheaper, related essential oils (like lemongrass) 39, undeclared solvents 39, or blending with entirely different plant species, such as Peppermint (*Mentha piperita*).40

Compounding this problem, simple organoleptic analysis (taste or smell) is unreliable for authentication. While the fresh plant is known for its lemon scent, an aqueous dry extract "will no longer exhibit its characteristic lemon-like odor".41 This makes it impossible to verify authenticity without advanced analytical methods like High-Performance Thin-Layer Chromatography (HPTLC).40

This high, difficult-to-detect risk of adulteration is not merely a quality control footnote; it is a fundamental threat to the interpretation of clinical efficacy. The conflicting results observed in the clinical literature, particularly for cognitive health 19, could be partially explained by this "garbage in, garbage out" principle. A trial using an unauthenticated, adulterated, or sub-potent commercial sample cannot be reliably compared to a trial using a high-potency, analytically-verified extract.

Furthermore, this raises a "Rosmarinic Acid Paradox." While RA is the predominant constituent 4 and the primary target for analytical standardization in major clinical trials 20, this reductionist approach may be insufficient. Data on antiviral activity, for example, clearly states that the *whole Melissa extract* possesses a "superior" selectivity index 42 and "superior virucidal activity" 43 when compared to its single constituents, including RA. This superiority is explicitly "imputable to multiple interactions of phytochemicals" 43, suggesting a synergistic entourage effect is responsible for the plant's full therapeutic potential.

## [pharmacology] Pharmacology and Mechanisms of Action

The clinical effects of *M. officinalis* are supported by several well-defined molecular mechanisms. The plant's constituents interact with key neurological and peripheral targets.

### **3.1. The Primary CNS Mechanism: GABAergic Modulation**

The most-cited mechanism, which provides the rationale for *M. officinalis*'s anxiolytic and sedative properties 1, is its profound modulation of the $\\gamma$-aminobutyric acid (GABA) system.1 GABA is the primary inhibitory neurotransmitter in the central nervous system.1

The plant's pharmacology suggests a sophisticated, dual-pronged attack on this system:

1. **Inhibition of GABA-Transaminase (GABA-T):** A methanol extract of *M. officinalis* was identified as a "potent in vitro inhibitor" of GABA-T.6 This enzyme is responsible for the catabolism (breakdown) of GABA in the synapse. Inhibiting GABA-T, a key target in anxiety therapy, effectively increases the concentration and prolongs the action of available GABA.6  
2. **Direct GABAA Receptor Stimulation:** Independent of its enzymatic effects, *M. officinalis* and its components also appear to act via "stimulation of the... $GABA\_A$ receptors".7 Binding to this receptor directly opens chloride channels, hyperpolarizing the neuron and causing an immediate inhibitory (calming) effect.

This dual mechanism—simultaneously pressing the inhibitory "brake" (GABAA stimulation) while cutting the line to the enzyme that *removes* the brake (GABA-T inhibition)—is mechanistically robust. It provides a powerful pharmacological explanation for the plant's long-standing traditional use as a calming agent and soporific.

### **3.2. The Cholinergic Pathway: Acetylcholinesterase (AChE) Inhibition**

A second major neurological pathway, which directly links *M. officinalis* to its traditional use for memory 32 and its modern trials in Alzheimer's Disease, is its influence on cholinergic activity.1

The specific mechanism is the **inhibition of acetylcholinesterase (AChE)**.1 AChE is the enzyme that breaks down the neurotransmitter acetylcholine; its inhibition is a "key therapeutic target for Alzheimer's management" 1, as it raises acetylcholine levels in the brain to support memory and cognition.45

Both rosmarinic acid 1 and terpenoids 1 have been identified as AChE inhibitors. An AChE-inhibitory guided fractionation of *M. officinalis* extract found that the most potent fractions contained *cis-* and \*trans-\*rosmarinic acid isomers.9 This mechanism has been validated *in vivo*. Studies in rats demonstrated that *M. officinalis* extract inhibits AChE activity in the hippocampus and can successfully ameliorate scopolamine-induced memory impairment.45

### **3.3. The Antiviral Mechanism: Blocking Herpes Simplex Virus (HSV) Cell Adsorption**

Distinct from its systemic neurological effects, *M. officinalis* possesses a unique peripheral mechanism of action against *Herpes simplex* viruses (HSV-1 and HSV-2), the cause of cold sores and genital herpes.33

*M. officinalis* essential oil exerts a "direct antiviral effect".12 This effect is not virucidal (it does not kill the virus) and is not effective after the virus has penetrated the host cell.12 Instead, its mechanism is highly specific:

**Inhibition of Viral Attachment:** The extract and its components work *before adsorption*.12 They **inhibit HSV-1 attachment to host cells** in a dose-dependent manner 42 by physically "blocking the receptors responsible for viral adsorption".33

This mechanism has a profound clinical advantage. Because the virus is prevented from entering the cell, it cannot replicate. This specific mode of action "rules out the development of resistance of the herpes virus" 13, a significant problem with standard nucleoside antiviral drugs.42 While rosmarinic acid is a main contributor to this effect 42, the whole extract, with its "multiple interactions of phytochemicals," demonstrates a superior antiviral selectivity index.42

### **Table 1: Bioactive Constituents and Primary Mechanisms of Action**

| Bioactive Class | Key Constituent(s) | Molecular Target | Mechanism of Action | Clinical Relevance |
| :---- | :---- | :---- | :---- | :---- |
| Phenolic Acids | Rosmarinic Acid, Caffeic Acid | GABA-Transaminase (GABA-T) | Inhibition of enzyme; increases synaptic GABA concentration 6 | Anxiolysis, Sedation, Sleep |
| (Unspecified) | (Unspecified) | $GABA\_A$ Receptor | Allosteric modulation or direct stimulation of the receptor 7 | Anxiolysis, Sedation, Sleep |
| Phenolic Acids, Terpenoids | Rosmarinic Acid Isomers, Terpenoids | Acetylcholinesterase (AChE) | Inhibition of enzyme; increases synaptic acetylcholine concentration 1 | Cognitive Enhancement, Alzheimer's Disease |
| Phenolic Acids, Volatiles | Rosmarinic Acid, Citral, etc. | Herpes Simplex Virus (HSV) Glycoproteins | Inhibition of viral attachment to host cell receptors 12 | Antiviral (Herpes Labialis) |
| Polyphenols, Flavonoids | (Various) | (Various) | Antioxidant, Anti-inflammatory 5 | Cardiometabolic Health, Neuroprotection |

## [clinical_evidence_cns] Clinical Evidence Review: CNS and Psychological Health

The clinical data supporting *M. officinalis*'s effects on the brain is extensive, though variable in its conclusions. This section appraises the human trial data for anxiety, sleep, and cognitive disorders.

### **4.1. Anxiety, Depression, and Stress**

The evidence for *M. officinalis* as an anxiolytic and anti-depressant is promising, supported by systematic reviews and several RCTs.

A 2021 systematic review and meta-analysis (PMID 34449930\) provides the highest level of evidence.14 This analysis found that *M. officinalis* supplementation led to a **statistically significant improvement in both mean anxiety scores (Standardized Mean Difference: \-0.98; 95% CI: \-1.63 to \-0.33; $p \= 0.003$)** and **mean depression scores (SMD: \-0.47; 95% CI: \-0.73 to \-0.21; $p \= 0.0005$)** compared to placebo.14

However, the authors of that same review strongly qualify this positive finding. They note that the results "should be interpreted with caution" 14 due to a **"high level of heterogeneity"** between the included studies and a "small number of clinical trials".14 This suggests that while a true effect is likely present, it is not uniform across different populations or preparations.

Individual RCTs provide more specific context:

* **In Cardiology Patients:** An 8-week, double-blind, placebo-controlled clinical trial (n=80) in patients with chronic stable angina found that supplementing with 3 g/day of *M. officinalis* capsules resulted in a **significant reduction in scores of depression, anxiety, and stress** (p \< 0.05) compared to the placebo group.49  
* **In Diabetic Patients:** A 12-week, double-blind clinical trial (n=60) in patients with type 2 diabetes (T2D) and comorbid depressive symptoms 50 tested 700 mg/day of a hydroalcoholic extract against a toasted flour placebo. The results showed a **statistically significant improvement in both depression (p \< 0.001) and anxiety (p \= 0.04)** scores in the *M. officinalis* group.50 No side effects were reported by the patients.50  
* **vs. Active Comparator (Fluoxetine):** An 8-week, double-blind RCT (n=45) in outpatients with mild-to-moderate depression took the provocative step of comparing 2 g/day of *M. officinalis* directly against 20 mg/day of fluoxetine (Prozac). The study found that *M. officinalis* had an antidepressant effect **"similar to fluoxetine"** (F \= 0.131, p \= 0.877, indicating no statistical difference between the two active groups).35 This finding is limited by the absence of a placebo group, which the authors acknowledge.35

### **4.2. Insomnia and Sleep Quality**

Mechanistically linked to its anxiolytic properties 29, the traditional use of *M. officinalis* as a sleep aid is now supported by objective clinical data.

The most compelling evidence comes from a recent prospective, double-blind, placebo-controlled, cross-over study (PMID 39683592\) that utilized a high-bioavailability *Melissa officinalis* Phytosome$^{\\texttrademark}$ (MOP) formulation.15 This trial demonstrated:

* **Subjective Improvement:** The MOP group experienced a **significant reduction in the Insomnia Severity Index (ISI) score** (p \= 0.003) compared to placebo.15 This was reflected in patient-reported outcomes, where **87% of participants in the MOP group reported improved sleep quality**, compared to only 30% in the placebo group (p \= 0.0003).15  
* **Objective Polysomnography Data:** Crucially, the study included objective sleep-stage analysis. It found that the MOP formulation **increased the duration of Slow Wave Sleep (SWS) by an average of 15%** while decreasing REM sleep by 10%.15 The increase in SWS, or "deep sleep," provides a physiological mechanism for the subjective reports of higher-quality, more restorative sleep.

Other trials support its use for sleep disturbances in various populations, including patients with chronic stable angina (3 g/day) 49 and women with Premenstrual Syndrome (1200 mg/day).1 *M. officinalis* is also frequently and effectively combined with *Valeriana officinalis* (valerian). A double-blind, placebo-controlled RCT (n=24) found a 600 mg dose of this combination "ameliorated the negative effects" of stress-induced anxiety 53, and another review of a trial (Cerny 1999\) noted 33% of the valerian/lemon balm group reported improved sleep versus 9.4% of placebo.1

### **4.3. The Cognitive Conundrum: Deconstructing Conflicting Evidence in MCI and Alzheimer's Disease**

This is the most complex and contradictory area of *M. officinalis* research. The evidence base is sharply divided between a foundational, positive trial in Alzheimer's Disease (AD) and a large, recent, negative trial in Mild Cognitive Impairment (MCI).

* The Foundational POSITIVE RCT (PMID 12810768):  
  This 4-month, parallel-group, placebo-controlled trial from 2003 (n=42) investigated the effect of 60 drops/day of M. officinalis extract in patients with mild-to-moderate Alzheimer's Disease.19 The results were highly positive. The extract produced a "significantly better outcome on cognitive function than placebo" on two primary endpoints: the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog; p \= 0.01) and the Clinical Dementia Rating (CDR; p \< 0.0001).19 A significant positive effect on agitation was also noted.19  
* The Recent NULL RCT (PMID 36502333):  
  In stark contrast, a large-scale (n=323), 96-week (approx. 2-year), randomized, double-blind, placebo-controlled trial from 2022 (published 2023\) came to the opposite conclusion.20 This study administered an M. officinalis extract standardized to 500 mg of Rosmarinic Acid (RA) per day to individuals with Subjective or Mild Cognitive Impairment (MCI), a much earlier stage than AD.20 The primary outcome was negative: "There were no significant differences in cognitive measures between the placebo and M. officinalis groups from baseline to 96 weeks".20  
* The CRITICAL SUBGROUP ANALYSIS (PMID 36502333):  
  However, buried within that negative result is a vital clue. The authors report: "However, based on the analysis of Clinical Dementia Rating Sum of Boxes scores in participants without hypertension, the score was found to be... \[improved\]".20 This subgroup of older adults without hypertension did show a significant cognitive benefit from the M. officinalis extract.20

To visualize this conflict, the key trial parameters are compared below.

### **Table 3: Comparative Analysis of Key *M. officinalis* RCTs in Cognition (MCI/AD)**

| Study (PMID) | Population | N | Duration | Intervention | Primary Outcome(s) | Overall Result | Key Subgroup Finding |
| :---- | :---- | :---- | :---- | :---- | :---- | :---- | :---- |
| **Akhondzadeh et al., 2003** 19 | Mild-to-Moderate Alzheimer's Disease (AD) | 42 | 4 months | 60 drops/day MO extract | ADAS-cog, CDR | **Significant Improvement** ($p \= 0.01$) | N/A (Reduced agitation, $p \= 0.03$) |
| **Noguchi-Shinohara et al., 2023** 20 | Subjective or Mild Cognitive Impairment (MCI) | 323 | 96 weeks | MO extract (500mg Rosmarinic Acid/day) | ADAS-cog, CDR-SB | **No Significant Difference** | **Significant Benefit** in participants *without hypertension* |

These two trials 19 were not, in fact, studying the same condition 57, and this population-mechanism mismatch is the most likely explanation for the divergent findings. The primary cognitive mechanism for *M. officinalis* is AChE inhibition 1, a therapeutic target shared with standard AD drugs like donepezil. The 2003 trial 19 targeted a population with established AD, a disease state *defined* by a significant cholinergic deficit, and found a strong positive effect. The 2022 trial 20 targeted MCI, a much earlier and more heterogeneous condition where a cholinergic deficit is not the primary or universal pathology. It is therefore highly plausible that the 2022 trial "failed" because it applied an AChE-inhibiting intervention to a population that was, on average, not cholinergic-deficient.

The subgroup analysis from the 2022 trial provides a "Rosetta Stone" that unifies the data.20 The fact that a cognitive benefit *only* became visible in participants *without* hypertension is a critical finding. Hypertension is a primary driver of vascular cognitive impairment.58 This suggests that in the full study group, the cognitive decline driven by "vascular noise" (i.e., damage from hypertension) was so significant that it completely drowned out the more subtle, non-vascular, neuroprotective signal from the *M. officinalis* extract. When this vascular cohort was removed, the true neuroprotective effect became statistically apparent.20 This theory is powerfully reinforced by the separate line of research (see Section 5.2) demonstrating that *M. officinalis* is *itself* an effective anti-hypertensive agent.34

### **4.4. Reconciling Oral vs. Aromatherapy Cognitive Data**

The data on *M. officinalis* aromatherapy for agitation in dementia is similarly conflicted. A 2002 4-week, placebo-controlled trial (n=72) in patients with severe dementia found that applying a lotion with *M. officinalis* essential oil twice daily **significantly reduced agitation** (a 35% reduction in CMAI score vs. 11% for placebo; p \< 0.0001) and improved quality of life.60

In contrast, a 2011 RCT (PMID 21335973\) found **no evidence** that *M. officinalis* aromatherapy was superior to placebo or donepezil for agitation in AD.61

The authors of the negative 2011 trial provide the most likely reconciliation. They noted a **"sizeable improvement in the placebo group"** and emphasized the potent **"non-specific benefits of touch and interaction"** involved in applying the lotion.61 This strongly implies that the positive result in the 2002 trial 60 was not a pharmacological effect of the *aroma*, but a "false positive" driven by the therapeutic benefit of the twice-daily, structured "touch and interaction" from a caregiver. This is supported by analyses suggesting aromatherapy routes may offer limited bioavailability and CNS effects compared to oral administration.56

## [clinical_evidence_systemic] Clinical Evidence Review: Systemic and Topical Applications

Beyond the central nervous system, *M. officinalis* has demonstrated significant, clinically-validated effects on cardiometabolic health and viral infections.

### **5.1. Cardiometabolic Health: Efficacy in Dyslipidemia**

Validating its traditional use as a "cardiac tonic" 16, a growing body of evidence supports *M. officinalis* as an effective agent for managing dyslipidemia.

This indication is supported by multiple systematic reviews and meta-analyses (SRMAs):

* **SRMA 1 (PMID 38575930):** A 2024 meta-analysis of 5 RCTs (n=302) 16 found that *M. officinalis* consumption led to a **significant decrease** in:  
  * **Total Cholesterol (TC):** SMD \-0.416 (p \< 0.001) 16  
  * **Triglycerides (TG):** SMD \-0.396 (p \= 0.001) 16  
  * LDL-Cholesterol ("Bad"): SMD \-0.23 (p \< 0.05) 16  
    The analysis found no statistically significant effect on HDL-Cholesterol ("Good").16 The authors noted the main limitations were the "limited number of eligible studies" and "small population size".16  
* **SRMA 2 (PMID 32614129):** A 2020 meta-analysis of 7 RCTs 62 similarly found a **significant reduction in total cholesterol (SMD: −0.26)** 62 and also noted a beneficial effect on systolic blood pressure.18 This review was also limited by a "low number of included studies" and a "serious risk of bias" in the primary literature.18

Individual RCTs confirm these findings. An 8-week trial (n=80) in stable angina patients using 3 g/day of *M. officinalis* **significantly reduced TG, TC, and LDL (p\<0.01)**.63 A 12-week RCT (n=62) in T2D patients using 700 mg/day **significantly reduced TG (p=0.04)** and, in this trial, *did* significantly *increase* HDL-c (p=0.05) 64, highlighting the heterogeneity noted in the SRMAs. Another T2D trial found *M. officinalis* significantly increased Apo A-I (a primary component of HDL).65

### **5.2. Impact on Hypertension**

Closely linked to its cardiometabolic and, as previously discussed, its cognitive effects, *M. officinalis* has shown promising and clinically significant results in lowering blood pressure.

* An RCT in patients with essential hypertension (PMID 34766389\) found that *M. officinalis* supplementation resulted in a **significant reduction in both systolic blood pressure (from 152.26 to 131.77 mmHg) and diastolic blood pressure (from 94.44 to 81.46 mmHg)** (p \=.005).34  
* An RCT in patients with Stage 1 hypertension (PMID 41101745\) found that *M. officinalis* produced the **greatest decrease in SBP (8 mmHg) and DBP (4 mmHg)**, proving superior to both placebo and another herbal intervention (p \< 0.001).59  
* The 12-week T2D trial (PMID 30548118\) also found a **significant reduction in systolic blood pressure (p=0.04)** as a secondary outcome.64

### **5.3. Topical Efficacy: A Robust Evidence Base for *Herpes Labialis***

Arguably the best-supported and most consistent clinical application for *M. officinalis* is its topical use for *Herpes labialis* (cold sores). This indication benefits from a clear mechanism (viral adsorption blocking, Section 3.3) and a strong base of clinical trial data.

A recent (2025) systematic review (PMID 40526027\) identified **7 RCTs encompassing 1,250 patients**.10 The review's conclusion was definitive: topical *M. officinalis* formulations **"consistently reduced pain intensity and swelling"** and, in some studies, demonstrated a **"significant decrease in lesion size compared with placebo or acyclovir"**.10

Much of this strong evidence is based on trials of "Lo-701," a standardized dried extract from *M. officinalis* leaves (70:1).13

* A foundational double-blind, placebo-controlled RCT (PMID 10589440\) in 66 patients with recurrent *herpes labialis* tested a 1% Lo-701 cream.13  
* The results were highly successful, showing a **"shortening of the healing period," "prevention of a spreading of the infection,"** and a **"rapid effect on typical symptoms"** including itching, tingling, burning, swelling, and tautness.13  
* A subsequent placebo-controlled double-blind study in 116 patients confirmed this antiviral activity, noting that the treatment is most effective when "initiated in the very early stages of the infection".68

The unique mechanism of action—preventing viral resistance by blocking adsorption 12—makes it a compelling clinical option.13

### **Table 4: Summary of Key RCTs for Topical *Melissa officinalis* in *Herpes Labialis***

| Study (PMID) | N | Intervention | Comparator | Key Outcomes | Mechanism |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Koytchev et al., 1999** 13 | 66 | 1% Lo-701 cream (standardized 70:1 extract) | Placebo cream | Shorter healing period, prevention of spreading, rapid reduction in itching, burning, swelling 13 | Inhibits viral adsorption; rules out resistance 12 |
| **Wölbling & Leonhardt, 1994** 68 | 116 | Dried Melissa extract cream | Placebo | "Corroborative evidence of antiviral activity" 68; most effective in early stages 68 | (as above) |
| **Anheyer et al., 2025 (SR)** 10 | 1,250 (7 RCTs) | Topical MO formulations | Placebo or Acyclovir | "Consistently reduced pain intensity and swelling," "significant decrease in lesion size" 10 | (as above) |

## [pharmacokinetics] Pharmacokinetics, Formulation, and Bioavailability

A significant gap exists between *M. officinalis*'s potent *in vitro* effects and its sometimes variable *in vivo* clinical results. This gap is largely explained by issues of pharmacokinetics (PK) and bioavailability.

### **6.1. The Rosmarinic Acid Problem: Human Absorption and Metabolism**

Rosmarinic acid (RA), the plant's key marker polyphenol 4, presents a significant pharmacokinetic challenge. The primary issue is its "fast metabolism" 27 and subsequent "poor bioavailability".15 This rapid breakdown and poor absorption are hypothesized to be the primary reasons why the potent biological activities demonstrated in cell models "have not always been observed in a reproducible manner in humans".28

A human PK study (PMID 25978046\) on a single dose of *M. officinalis* extract containing 500 mg of RA found it to be safe and tolerable.29 This study also produced a critical clinical directive: **food intake "increased the exposure of rosmarinic acid and delayed absorption"**.69 This suggests that to maximize absorption, *M. officinalis* extracts should be taken with food.

### **6.2. Next-Generation Extracts: The Impact of Phytosome Technology**

To overcome the challenge of poor bioavailability, next-generation formulations have been developed. The most prominent in the research is the Phytosome$^{\\texttrademark}$ technology (e.g., MOP, Relissa$^{\\texttrademark}$), which complexes the *M. officinalis* aqueous extract with a phospholipid (sunflower) carrier to enhance absorption.29 This specific formulation is standardized to **17%–23% hydroxycinnamic acid derivatives**.29

This advanced formulation has demonstrated superior potency both *in vitro* and *in vivo*.

* **Superior *In Vitro* Potency:** A head-to-head study 8 comparing the Phytosome$^{\\texttrademark}$ formulation (Relissa$^{\\texttrademark}$) to an unformulated dry extract found the Phytosome$^{\\texttrademark}$ version was **dramatically more potent** at its primary CNS mechanism. For **GABA-T inhibition**, the IC50 (concentration required to inhibit 50% of the enzyme) was **0.064 mg/mL for the Phytosome$^{\\texttrademark}$** versus **0.27 mg/mL for the unformulated extract**. This indicates the Phytosome$^{\\texttrademark}$ formulation is **over 4.2 times more potent** at inhibiting the breakdown of GABA.8  
* **Superior *Clinical* Efficacy:** This *in vitro* superiority has translated to positive clinical trials. An RCT using 400 mg/day of Relissa$^{\\texttrademark}$ for 3 weeks found **significant improvements in depressive mood, anxiety, and stress (all p values \<0.001)**.29 Similarly, the MOP (Phytosome$^{\\texttrademark}$) RCT (PMID 39683592\) was the trial that demonstrated **significant improvements in sleep quality, insomnia scores (p=0.003), and objective SWS sleep duration**.15

A curious contradiction exists in this data, however. The MOP *sleep* trial 15 explicitly reported **"No significant changes in... anxiety levels"**.28 This is in direct conflict with the Relissa$^{\\texttrademark}$ *anxiety* trial, which found a highly significant benefit.29 This divergence, despite both using Phytosome$^{\\texttrademark}$ technology, may be due to a "floor effect" (the sleep trial participants had baseline anxiety levels too low to be further reduced) or it may suggest a more complex pharmacological nuance: the high-bioavailability formulation's potent GABA-T inhibition 8 may act as a powerful *sedative* (affecting sleep) without fully engaging the other neurological pathways (e.g., serotonergic 1) required to modulate the *affective* state of anxiety.

## [safety] Expert Analysis: Safety, Contraindications, and Interactions

A rigorous assessment of *Melissa officinalis*'s safety profile is essential for clinical use. While generally well-tolerated, several critical contraindications and interaction risks are documented.

### **7.1. Toxicological Profile and General Safety**

* **Human Clinical Data:** *M. officinalis* is consistently described in reviews as "substantially safe".21 Across multiple RCTs, including those using high doses (3 g/day) 49 or long durations (12 weeks) 51, the systematic reporting finds **"No serious adverse events"** 18 or "No side effects were reported".50 One trial noted minor events like bruising and headache, but at rates similar to the placebo group.47  
* **Hepatotoxicity (Liver Safety):** The U.S. National Institutes of Health LiverTox database states that lemon balm extracts are "generally recognized as safe" (GRAS) and have **"not been linked to serum aminotransferase elevations... or... instances of clinically apparent acute liver injury"**.22  
* **Animal Toxicology:** Preclinical toxicology supports a high safety threshold. The oral LD50 in rats is reported as $\\ge$5000 mg/kg.71 A 90-day subchronic toxicity study in rats established a No-Observed-Adverse-Effect-Level (NOAEL) of at least 3,046.1 mg/kg/day, an extremely high dose.72 However, one 30-day rat study administering high doses (600 and 1200 mg/kg) *did* report histopathological lesions in the liver and kidneys, suggesting long-term, high-dose use warrants caution.73

### **7.2. Case Report Analysis: Dependence and Withdrawal**

While RCTs report high safety, a single, critical case report (PMID 4384870\) highlights a significant potential risk associated with long-term use.26

The report details a 30-year-old patient admitted to an emergency department with **"restlessness, tremor, distractibility, and sweating"**.26 These symptoms began after the patient *discontinued* long-term consumption of *M. officinalis*. The Naranjo Causality Scale, a tool for assessing adverse drug reactions, yielded a score of 6, indicating the withdrawal symptoms were "likely" due to *M. officinalis*.26 The patient's symptoms were successfully resolved with the administration of **Clonazepam**, a benzodiazepine.26

This case report is not merely an anecdote; it serves as a powerful *in vivo* confirmation of *M. officinalis*'s potent GABAergic mechanism of action. The patient's symptoms (anxiety, tremor) are classic hallmarks of withdrawal from other GABAergic agonists, such as benzodiazepines or alcohol. The fact that a benzodiazepine (Clonazepam) was required to resolve the symptoms strongly implies the patient was in a state of GABAergic hypofunction. This suggests that chronic, high-dose use of *M. officinalis*, via its potent GABAA stimulation and GABA-T inhibition 6, had caused physical dependence. Upon cessation, the patient's downregulated system was "unmasked," precipitating withdrawal. This confirms the MoA is clinically potent and flags a clear risk of dependence.

### **7.3. Critical Contraindications: Thyroid Disease and Pregnancy**

* **Pregnancy and Lactation:** There is insufficient reliable information. It has been "reported to be unsafe".48 The consensus recommendation is to **"Stay on the safe side and avoid use"**.23  
* **Thyroid Disease:** This is the single most important contraindication for *M. officinalis*. Clinical sources state unequivocally: **"Avoid lemon balm if you have thyroid disease"**.23 It is considered "unsafe... in patients with thyroid disorders".48  
  * **Mechanism:** *M. officinalis* "may change thyroid function, reduce thyroid hormone levels, and **interfere with thyroid hormone replacement therapy**".23 *In vitro* studies show its principles **"may block the binding of TSH to its receptor"**.24  
  * **Evidence:** This mechanism was confirmed in an animal model of hyperthyroidism, where *M. officinalis* extract *reversed* the effect of Eltroxin (synthetic T4), causing TSH levels to rise and T3/T4 levels to fall.25

This specific mechanism, however, is a "double-edged sword." For a patient with **hypothyroidism** (underactive thyroid) on hormone replacement (e.g., Levothyroxine), *M. officinalis* is clearly dangerous. By blocking TSH 24 and antagonizing T4 25, it could render their medication ineffective.23

Conversely, for a patient with **hyperthyroidism** (overactive thyroid), such as Graves' Disease, this *exact same mechanism* is potentially therapeutic. *In vitro* data shows that *M. officinalis* constituents inhibit the pathogenic Graves'-IgG antibodies from binding to and activating the TSH receptor.74 This is supported by two human case reports where patients with Graves' Disease who could not tolerate anti-thyroid medication (Methimazole) successfully achieved a euthyroid (normal) state using only a bugleweed (*Lycopus* spp.) and *lemon balm* tincture.75 Therefore, *M. officinalis* is strongly contraindicated in hypothyroidism but is being empirically investigated as a treatment for hyperthyroidism.

### **7.4. Drug-Drug Interactions (DDI)**

* Pharmacodynamic DDI (Clinically Relevant):  
  The most significant interaction risk is with other sedatives. Due to its known hypnotic 76 and GABAergic effects, M. officinalis "potentiates the effects of other central nervous system depressants, such as alcohol".26 It should be used with extreme caution, or avoided entirely, in combination with alcohol, benzodiazepines, Z-drugs, and other sedative-hypnotics.78  
* Pharmacokinetic DDI (Theoretical):  
  There is a theoretical risk of pharmacokinetic interactions. Rosmarinic acid has been reported as a "weak or moderate inhibitor" of drug-metabolizing CYP450 enzymes in vitro.47 M. officinalis is listed among herbs with a potential to interact with synthetic drugs.80 However, this risk appears low in vivo; a human trial in AD patients "did not observe any apparent interactions" with concomitant medications.47 A theoretical risk also exists for competition with P-glycoprotein (P-gp) efflux pump substrates, such as certain antiretroviral drugs.81

### **Table 5: Clinician's Reference: Safety, Contraindications, and Drug Interactions**

| Risk Category | Finding | Mechanism | Clinical Implication | Source(s) |
| :---- | :---- | :---- | :---- | :---- |
| **Critical Contraindication** | **Thyroid Disease** | Interferes with thyroid function, reduces TSH binding, and lowers T3/T4 levels. | **AVOID** in patients with thyroid disease, especially **hypothyroidism**. May block efficacy of hormone replacement therapy. | 23 |
| **Contraindication** | **Pregnancy & Lactation** | Insufficient safety data. | **AVOID** use due to lack of evidence. | 23 |
| **Major Interaction** | **Pharmacodynamic DDI (Sedatives)** | Potentiates effects of other CNS depressants. | **AVOID** or use with extreme caution with **alcohol, benzodiazepines, and other sedatives**. | 26 |
| **Potential Risk** | **Dependence & Withdrawal** | Case report of withdrawal symptoms (anxiety, tremor) after long-term use. | Counsel patients on risk of physical dependence with chronic, high-dose use. Tapering may be required. | 26 |
| **General Safety** | **Hepatotoxicity (Liver)** | Generally Recognized as Safe (GRAS). Not linked to liver injury in human trials. | Considered safe for the liver at recommended doses. | 22 |
| **Theoretical Risk** | **Pharmacokinetic DDI (CYP/P-gp)** | Weak *in vitro* inhibitor of CYP450; may compete for P-gp. | Low *in vivo* risk, but monitor patients on narrow-therapeutic-index drugs. | 47 |

## [conclusions] Concluding Synthesis and Future Directives

### **8.1. Summary of Evidence by Indication**

This comprehensive analysis confirms *Melissa officinalis* L. as a potent medicinal herb with multi-target pharmacology, supported by a heterogeneous but compelling body of clinical evidence.

* **Strong Evidence:** The evidence for **topical *M. officinalis* in *Herpes labialis*** is robust, consistent, and supported by a large patient population (n=1,250) across 7 RCTs and a clear, resistance-avoidant mechanism of action.10  
* **Moderate Evidence:** The evidence for oral use in **mild-to-moderate anxiety/depression** 14, **insomnia** 15, and **dyslipidemia** (TC, TG, LDL) 16 is positive and statistically significant according to systematic reviews. This evidence is classified as "moderate" only because the reviews themselves cite significant limitations, including "high heterogeneity," "small number of studies," and "serious risk of bias".14  
* **Conflicting Evidence:** The data for **cognitive decline** is in a state of direct conflict. The positive 2003 trial in AD 19 and the negative 2022 trial in MCI 20 are likely irreconcilable due to a fundamental population-mechanism mismatch.  
* **Emerging Evidence:** A cluster of recent, positive RCTs 34 provides strong, emerging evidence for *M. officinalis* as a clinically significant **anti-hypertensive** agent.

### **8.2. Key Research Gaps and Future Directives**

The existing data highlights several critical gaps that must be addressed by future research:

1. **Resolve the Cognitive Conflict:** The single most pressing research need is a large-scale, long-term RCT to replicate the 2003 Akhondzadeh trial 19 in a modern, well-defined *mild-to-moderate Alzheimer's Disease* population.  
2. **Investigate the Hypertension Subgroup:** A follow-up to the 2022 Noguchi-Shinohara trial 20 is required, specifically a pre-specified RCT in *MCI patients without hypertension*, to confirm the subgroup finding.20  
3. **Head-to-Head Formulation Trials:** The superior *in vitro* 8 and clinical 15 data for Phytosome$^{\\texttrademark}$ formulations necessitates a direct, head-to-head RCT comparing them against standard extracts to determine if enhanced bioavailability is the key to reproducible efficacy.  
4. **Deconstruct the Thyroid Interaction:** The case reports on Graves' Disease 75 are clinically fascinating. An RCT is warranted to investigate *M. officinalis* (perhaps in combination with *Lycopus* spp.) as a potential primary or adjunct therapy for *hyper*thyroidism.  
5. **Address Product Integrity:** Given the high risk of adulteration 30, future trials must use and report rigorous third-party analytical authentication (e.g., HPTLC) of their study materials to ensure reproducibility.  
6. **Confirm the Withdrawal Risk:** The case report on dependence 26 is concerning. A prospective, observational study monitoring for withdrawal symptoms upon cessation of long-term, high-dose use is needed to quantify this risk.

## [references] Bibliography & References

1. Clinical Efficacy and Tolerability of Lemon Balm (Melissa officinalis L.) in Psychological Well-Being: A Review \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11510126/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11510126/)  
2. Clinical Efficacy and Tolerability of Lemon Balm (Melissa officinalis L.) in Psychological Well-Being: A Review \- MDPI, accessed November 11, 2025, [https://www.mdpi.com/2072-6643/16/20/3545](https://www.mdpi.com/2072-6643/16/20/3545)  
3. Melissa officinalis: Composition, Pharmacological Effects and Derived Release Systems—A Review \- PMC, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8998931/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8998931/)  
4. Rosmarinic Acid and Melissa officinalis Extracts Differently Affect Glioblastoma Cells \- PMC, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5027300/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5027300/)  
5. Anti-inflammatory and Antioxidant Effects of Melissa officinalis Extracts: A Comparative Study \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/36060902/](https://pubmed.ncbi.nlm.nih.gov/36060902/)  
6. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/19165747/](https://pubmed.ncbi.nlm.nih.gov/19165747/)  
7. Melissa officinalis L. \- A review of its traditional uses, phytochemistry and pharmacology, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/27167460/](https://pubmed.ncbi.nlm.nih.gov/27167460/)  
8. An in vitro analysis of an innovative standardized phospholipid carrier-based Melissa officinalis L. extract as a potential neuromodulator for emotional distress and related conditions \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10965792/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10965792/)  
9. Acetylcholinesterase inhibitory guided fractionation of Melissa officinalis L \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/19070498/](https://pubmed.ncbi.nlm.nih.gov/19070498/)  
10. Herbal Medicine for Treating Herpes Labialis: A Systematic Review \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/40526027/](https://pubmed.ncbi.nlm.nih.gov/40526027/)  
11. Melissa officinalis: Clinical Trials \- American Botanical Council, accessed November 11, 2025, [https://www.herbalgram.org/resources/herbmedpro/herb-list/melissa-officinalis?subCat=Clinical%20Trials](https://www.herbalgram.org/resources/herbmedpro/herb-list/melissa-officinalis?subCat=Clinical+Trials)  
12. Melissa officinalis oil affects infectivity of enveloped herpesviruses \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/18693101/](https://pubmed.ncbi.nlm.nih.gov/18693101/)  
13. Balm mint extract (Lo-701) for topical treatment of recurring herpes labialis \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/10589440/](https://pubmed.ncbi.nlm.nih.gov/10589440/)  
14. The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: A systematic review and meta-analysis \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/34449930/](https://pubmed.ncbi.nlm.nih.gov/34449930/)  
15. Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/39683592/](https://pubmed.ncbi.nlm.nih.gov/39683592/)  
16. Effects of Melissa officinalis (lemon balm) consumption on serum lipid profile: a meta-analysis of randomized controlled trials \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/38575930/](https://pubmed.ncbi.nlm.nih.gov/38575930/)  
17. Effects of Melissa officinalis (lemon balm) consumption on serum lipid profile: a meta-analysis of randomized controlled trials \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10996117/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10996117/)  
18. Effects of Melissa officinalis (Lemon Balm) on cardio-metabolic outcomes: A systematic review and meta-analysis \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/32614129/](https://pubmed.ncbi.nlm.nih.gov/32614129/)  
19. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/12810768/](https://pubmed.ncbi.nlm.nih.gov/12810768/)  
20. Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/36502333/](https://pubmed.ncbi.nlm.nih.gov/36502333/)  
21. An Updated Review on The Properties of Melissa officinalis L.: Not Exclusively Anti-anxiety, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/35730441/](https://pubmed.ncbi.nlm.nih.gov/35730441/)  
22. Lemon Balm \- LiverTox \- NCBI Bookshelf \- NIH, accessed November 11, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK600583/](https://www.ncbi.nlm.nih.gov/books/NBK600583/)  
23. Lemon Balm: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews, accessed November 11, 2025, [https://www.webmd.com/vitamins/ai/ingredientmono-437/lemon-balm](https://www.webmd.com/vitamins/ai/ingredientmono-437/lemon-balm)  
24. In vitro assay of thyroid disruptors affecting TSH-stimulated adenylate cyclase activity, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/14759065/](https://pubmed.ncbi.nlm.nih.gov/14759065/)  
25. Melissa officinalis extract palliates redox imbalance and inflammation associated with hyperthyroidism-induced liver damage by regulating Nrf-2/ Keap-1 gene expression in γ-irradiated rats \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10832092/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10832092/)  
26. Does Melissa Officinalis Cause Withdrawal or Dependence? \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4384870/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4384870/)  
27. Rosmarinic Acid-Human Pharmacokinetics and Health Benefits \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/33285594/](https://pubmed.ncbi.nlm.nih.gov/33285594/)  
28. Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study \- MDPI, accessed November 11, 2025, [https://www.mdpi.com/2072-6643/16/23/4199](https://www.mdpi.com/2072-6643/16/23/4199)  
29. The possible “calming effect” of subchronic supplementation of a standardised phospholipid carrier-based Melissa officinalis L. extract in healthy adults with emotional distress and poor sleep conditions: results from a prospective, randomised, double-blinded, placebo-controlled clinical trial \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10620697/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10620697/)  
30. Mushroom and botanical identity testing reveals the top 20 ingredients to 'watch out for', accessed November 11, 2025, [https://nutraceuticalbusinessreview.com/alkemist-labs-mushroom-botanical-identity-testing-late-2024](https://nutraceuticalbusinessreview.com/alkemist-labs-mushroom-botanical-identity-testing-late-2024)  
31. Bioactive Compounds, Medicinal Benefits, and Contemporary Extraction Methods for Lemon Balm (Melissa officinalis) \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/40927050/](https://pubmed.ncbi.nlm.nih.gov/40927050/)  
32. Melissa officinalis L., a valuable medicine plant: A review \- Academic Journals, accessed November 11, 2025, [https://academicjournals.org/article/article1380713061\_Moradkhani%20et%20al.pdf](https://academicjournals.org/article/article1380713061_Moradkhani%20et%20al.pdf)  
33. Antiviral Potential of Melissa officinalis L.: A Literature Review \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9841880/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841880/)  
34. Effect of Melissa officinalis on systolic and diastolic blood pressures in essential hypertension: A double-blind crossover clinical trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/34766389/](https://pubmed.ncbi.nlm.nih.gov/34766389/)  
35. A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/32620104/](https://pubmed.ncbi.nlm.nih.gov/32620104/)  
36. A Comprehensive Review of Rosmarinic Acid: From Phytochemistry to Pharmacology and Its New Insight \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9143754/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9143754/)  
37. An Updated Review on The Properties of Melissa officinalis L.: Not Exclusively Anti-anxiety, accessed November 11, 2025, [https://www.imrpress.com/journal/FBS/14/2/10.31083/j.fbs1402016/htm](https://www.imrpress.com/journal/FBS/14/2/10.31083/j.fbs1402016/htm)  
38. Botanical Ingredient Forensics: Detection of Attempts to Deceive Commonly Used Analytical Methods for Authenticating Herbal Dietary and Food Ingredients and Supplements \- PMC \- NIH, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9972475/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9972475/)  
39. Melissa Adulteration \- Aromatic Plant Research Center, accessed November 11, 2025, [https://www.aromaticplant.org/post/melissa-adulteration](https://www.aromaticplant.org/post/melissa-adulteration)  
40. Melissa officinalis (leaf) \- AHPA Botanical Identity References Compendium, accessed November 11, 2025, [http://www.botanicalauthentication.org/index.php/Melissa\_officinalis\_(leaf)](http://www.botanicalauthentication.org/index.php/Melissa_officinalis_\(leaf\))  
41. Exhaustive Analytical Profiling of Phytocompounds in Botanical Active Ingredients: Fighting the Global Prevalence of Adulterated Botanical Ingredients for Cosmetics \- MDPI, accessed November 11, 2025, [https://www.mdpi.com/2079-9284/12/2/63](https://www.mdpi.com/2079-9284/12/2/63)  
42. Melissa Officinalis Extract Inhibits Attachment of Herpes Simplex Virus in Vitro \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/22377592/](https://pubmed.ncbi.nlm.nih.gov/22377592/)  
43. An Updated Review on The Properties of Melissa officinalis L.: Not Exclusively Anti-anxiety \- Semantic Scholar, accessed November 11, 2025, [https://pdfs.semanticscholar.org/1f53/1b8d9636319e39beac787705c89fe4fd86bd.pdf](https://pdfs.semanticscholar.org/1f53/1b8d9636319e39beac787705c89fe4fd86bd.pdf)  
44. Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11644815/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11644815/)  
45. Memory-improving activity of Melissa officinalis extract in naïve and scopolamine-treated rats \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4311288/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4311288/)  
46. Influence of the Melissa officinalis Leaf Extract on Long-Term Memory in Scopolamine Animal Model with Assessment of Mechanism of Action, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4864554/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4864554/)  
47. Safety and efficacy of Melissa officinalis extract containing rosmarinic acid in the prevention of Alzheimer's disease progression \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7596544/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7596544/)  
48. Melissa officinalis L: A Review Study With an Antioxidant Prospective \- PMC, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5871149/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5871149/)  
49. The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/29908682/](https://pubmed.ncbi.nlm.nih.gov/29908682/)  
50. The effects of melissa officinalis on depression and anxiety in type 2 diabetes patients with depression: a randomized double-blinded placebo-controlled clinical trial \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10152712/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10152712/)  
51. The effects of melissa officinalis on depression and anxiety in type 2 diabetes patients with depression: a randomized double-blinded placebo-controlled clinical trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/37131158/](https://pubmed.ncbi.nlm.nih.gov/37131158/)  
52. Effects of Herbal combination (Melissa officinalis L. and Nepeta menthoides Boiss. & Buhse) on insomnia severity, anxiety and depression in insomniacs: Randomized placebo controlled trial \- PMC \- NIH, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6303415/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6303415/)  
53. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/16444660/](https://pubmed.ncbi.nlm.nih.gov/16444660/)  
54. Valerian for Sleep: A Systematic Review and Meta-Analysis \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4394901/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4394901/)  
55. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial \- NIH, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC1738567/](https://pmc.ncbi.nlm.nih.gov/articles/PMC1738567/)  
56. Unraveling the Effects of Melissa officinalis L. on Cognition and Sleep Quality: A Narrative Review \- MDPI, accessed November 11, 2025, [https://www.mdpi.com/1422-0067/26/21/10566](https://www.mdpi.com/1422-0067/26/21/10566)  
57. Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms \- MDPI, accessed November 11, 2025, [https://www.mdpi.com/1422-0067/26/21/10631](https://www.mdpi.com/1422-0067/26/21/10631)  
58. Exploring the association between hypertension and cognitive impairment: Evidence‐based insights \- PMC \- NIH, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11166671/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11166671/)  
59. Comparison of the effects of Echium amoenum and Melissa officinalis on hypertension in stage 1 hypertensive patients: A randomized, triple-blind, three-arm clinical trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/41101745/](https://pubmed.ncbi.nlm.nih.gov/41101745/)  
60. Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia: The Results of a Double-Blind, Placebo-Controlled Trial With Melissa \- ResearchGate, accessed November 11, 2025, [https://www.researchgate.net/publication/11238078\_Aromatherapy\_as\_a\_Safe\_and\_Effective\_Treatment\_for\_the\_Management\_of\_Agitation\_in\_Severe\_Dementia\_The\_Results\_of\_a\_Double-Blind\_Placebo-Controlled\_Trial\_With\_Melissa](https://www.researchgate.net/publication/11238078_Aromatherapy_as_a_Safe_and_Effective_Treatment_for_the_Management_of_Agitation_in_Severe_Dementia_The_Results_of_a_Double-Blind_Placebo-Controlled_Trial_With_Melissa)  
61. A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/21335973/](https://pubmed.ncbi.nlm.nih.gov/21335973/)  
62. Effects of Melissa officinalis (Lemon Balm) on cardio‐metabolic outcomes: A systematic review and meta‐analysis \- ResearchGate, accessed November 11, 2025, [https://www.researchgate.net/publication/342642861\_Effects\_of\_Melissa\_officinalis\_Lemon\_Balm\_on\_cardio-metabolic\_outcomes\_A\_systematic\_review\_and\_meta-analysis](https://www.researchgate.net/publication/342642861_Effects_of_Melissa_officinalis_Lemon_Balm_on_cardio-metabolic_outcomes_A_systematic_review_and_meta-analysis)  
63. The effects of Melissa officinalis (lemon balm) in chronic stable angina on serum biomarkers of oxidative stress, inflammation and lipid profile \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/30045422/](https://pubmed.ncbi.nlm.nih.gov/30045422/)  
64. Efficacy of Melissa officinalis L. (lemon balm) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: A randomized, double-blind, clinical trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/30548118/](https://pubmed.ncbi.nlm.nih.gov/30548118/)  
65. Safety and efficacy of Melissa officinalis (lemon balm) on ApoA-I, Apo B, lipid ratio and ICAM-1 in type 2 diabetes patients: A randomized, double-blinded clinical trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/30219475/](https://pubmed.ncbi.nlm.nih.gov/30219475/)  
66. Review of Whole Plant Extracts With Activity Against Herpes Simplex Viruses In Vitro and In Vivo \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7894602/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7894602/)  
67. Melissa officinalis (Lemon Balm) to Treat Herpes Labialis |, accessed November 11, 2025, [https://www.clinician.com/articles/28918-melissa-officinalis-lemon-balm-to-treat-herpes-labialis](https://www.clinician.com/articles/28918-melissa-officinalis-lemon-balm-to-treat-herpes-labialis)  
68. Local therapy of herpes simplex with dried extract from Melissa officinalis \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/23195812/](https://pubmed.ncbi.nlm.nih.gov/23195812/)  
69. Pharmacokinetics, Safety and Tolerability of Melissa Officinalis Extract Which Contained Rosmarinic Acid in Healthy Individuals: A Randomized Controlled Trial \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/25978046/](https://pubmed.ncbi.nlm.nih.gov/25978046/)  
70. The possible “calming effect” of subchronic supplementation of a standardised phospholipid carrier-based Melissa officinalis L. extract in healthy adults with emotional distress and poor sleep conditions: results from a prospective, randomised, double-blinded, placebo-controlled clinical trial \- Frontiers, accessed November 11, 2025, [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1250560/full](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1250560/full)  
71. CHEMICAL SAFETY DATA SHEET \- Biolandes, accessed November 11, 2025, [https://www.biolandes.com/wp-content/uploads/fiche-securite-B625.pdf](https://www.biolandes.com/wp-content/uploads/fiche-securite-B625.pdf)  
72. Toxicological safety evaluation of an aqueous lemon balm (Melissa officinalis) extract, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/38461950/](https://pubmed.ncbi.nlm.nih.gov/38461950/)  
73. Toxicological evaluation of chronic oral administration of Melissa officinalis hydro-ethanol extract in Sprague-Dawley rats | Veterinary Science Development \- PAGEPress, accessed November 11, 2025, [https://www.pagepress.org/journals/vsd/article/view/6298/7224](https://www.pagepress.org/journals/vsd/article/view/6298/7224)  
74. Extracts and auto-oxidized constituents of certain plants inhibit the receptor-binding and the biological activity of Graves' immunoglobulins \- PubMed, accessed November 11, 2025, [https://pubmed.ncbi.nlm.nih.gov/2985357/](https://pubmed.ncbi.nlm.nih.gov/2985357/)  
75. Two Cases of Graves' Hyperthyroidism Treated With Homeopathic Remedies Containing Herbal Extracts from Lycopus spp. and Melissa officinalis \- NIH, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8090196/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8090196/)  
76. Hypnotic effect of Coriandrum sativum, Ziziphus jujuba, Lavandula angustifolia and Melissa officinalis extracts in mice \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4698858/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4698858/)  
77. Hypnotic effect of Coriandrum sativum, Ziziphus jujuba, Lavandula angustifolia and Melissa officinalis extracts in mice \- ResearchGate, accessed November 11, 2025, [https://www.researchgate.net/publication/291136336\_Hypnotic\_effect\_of\_Coriandrum\_sativum\_Ziziphus\_jujuba\_Lavandula\_angustifolia\_and\_Melissa\_officinalis\_extracts\_in\_mice](https://www.researchgate.net/publication/291136336_Hypnotic_effect_of_Coriandrum_sativum_Ziziphus_jujuba_Lavandula_angustifolia_and_Melissa_officinalis_extracts_in_mice)  
78. Lemon Balm and Thyroid: Benefits, Risks, and Dietary Considerations \- Performance Lab, accessed November 11, 2025, [https://www.performancelab.com/blogs/sleep/lemon-balm-and-thyroid-health](https://www.performancelab.com/blogs/sleep/lemon-balm-and-thyroid-health)  
79. Melissa officinalis L. as a Nutritional Strategy for Cardioprotection \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8100328/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8100328/)  
80. Herb–drug interactions: an overview of systematic reviews \- PMC \- PubMed Central, accessed November 11, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3575928/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3575928/)  
81. The effects of Melissa officinalis (lemon balm) in chronic stable angina on serum biomarkers of oxidative stress, inflammation and lipid profile \- ResearchGate, accessed November 11, 2025, [https://www.researchgate.net/publication/324910443\_The\_effects\_of\_Melissa\_officinalis\_lemon\_balm\_in\_chronic\_stable\_angina\_on\_serum\_biomarkers\_of\_oxidative\_stress\_inflammation\_and\_lipid\_profile](https://www.researchgate.net/publication/324910443_The_effects_of_Melissa_officinalis_lemon_balm_in_chronic_stable_angina_on_serum_biomarkers_of_oxidative_stress_inflammation_and_lipid_profile)